Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Rovco designs an autonomous underwater vehicle or AUV and remotely operated underwater vehicle or ROV technologies and support services that optimizes how people manage and inspect subsea assets. Its technology offers the process of 3D photogrammetry that involves using high-resolution photos of a static object or site area taken from multiple angles and processed to generate a 3D vector model from point cloud data, enabling oil, gas, and renewables industry clients to evaluate their subsea assets for damage, corrosion or determining levels of marine growth and benefit from inspection related cost savings.
Lineat is a manufacturer specializing in fiber tape products, particularly focusing on carbon fiber tapes produced through aligned formable fiber technology. This innovative approach allows for the creation of aligned discontinuous fiber tapes that demonstrate mechanical performance comparable to traditional continuous fiber composites. By simplifying the composite manufacturing process, Lineat enhances formability and streamlines both manual and automated operations. Additionally, the company has implemented a closed-loop water circulation system aimed at improving lifecycle assessment (LCA), reflecting its commitment to sustainability in production practices.
MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the progression of challenging diseases, particularly rare indications, while also engaging in partnerships for broader applications. Their work enables healthcare professionals to potentially halt the decline associated with dystrophy and neurodegeneration.
AMLo Biosciences Ltd is a company focused on developing diagnostic solutions for melanoma, specifically through its prognostic test, AMBLor. This test aims to accurately predict the risk of disease progression in patients diagnosed with early AJCC Stage I and Stage II melanoma. By identifying two specific proteins that are lost in high-risk melanomas, AMBLor helps to stratify patients for appropriate treatment and follow-up care. The company, incorporated in 2017 and based in Newcastle upon Tyne, United Kingdom, seeks to reduce the psychological burden on patients while also providing cost savings to health authorities by minimizing unnecessary patient surveillance.
Vaarst is a developer of robotic analytic solutions specifically tailored for ocean applications. The company utilizes advanced computer vision technology to capture, store, manage, and analyze data effectively. Its platform incorporates live streaming and geo-referencing capabilities, which help businesses significantly reduce inspection costs and the time required for examination. By streamlining these processes, Vaarst offers a more efficient alternative to traditional methods, enhancing the overall effectiveness of marine operations.
A vibrant UK based small business, offering schools and colleges some wonderful and exciting educational and cultural tours to schools and colleges throughout the UK, Europe, and beyond. Our head office is in the centre of Birmingham and our young, multi-lingual, and exceptionally talented(!) staff team is driven by ensuring all our customers are given the best possible price and service.
Kallik is a global provider of labeling content management and artwork generation solutions tailored for regulated markets, including pharmaceuticals, medical devices, cosmetics, and chemicals. The company develops enterprise software that aids manufacturers in efficiently managing their labeling and artwork processes. By offering centralized messaging content, Kallik enables clients to produce print-ready artwork for packaging and labeling, ensuring compliance with industry regulations. This streamlined approach enhances efficiency and helps clients navigate the complexities of labeling in their respective sectors.
Igloo Vision Limited specializes in designing, developing, and manufacturing immersive 360º projection technologies tailored for simulation, visualization, and experiential applications. The company offers a range of virtual reality tools, including media players, software interfaces, projector rigs, and immersive projection environments such as domes and cylinders. These projection spaces facilitate collaborative activities, training sessions, design meetings, and stakeholder engagement, accommodating groups ranging from 5 to 750 participants. Established in 2008 and headquartered in Craven Arms, United Kingdom, Igloo Vision has built a strong reputation over its decade-long operation, working with numerous prominent brands and delivering hundreds of events and installations globally. The company’s technologies support a variety of applications, including live feeds, video conferencing, and animated audiovisuals, providing a versatile platform for immersive experiences.
Prism Network Ltd is provides disaster recovery and building repair service to insurance and property sectors in the United Kingdom. Its services include building reinstatement, roofing work, electrical works, plumbing and gas works, non-intrusive leak detection, flood clean-up, flood restoration, water removal, structural drying, subsidence, structural surveys, structural repairs, wet carpet restoration, fire damage restoration, fire damage repair, fire clean-up, disaster clean-up, full contents restoration, asbestos testing and removal, sewage clean-up, leak and moisture detection, mould remediation, air quality testing, trauma clean-up, lightning damage, mould removal, mould testing, air quality sampling, and crime scene clean-up services.
Phoenix Health & Safety provide Health and Safety training courses, accredited by IOSH, NEBOSH, ConstructionSkills and CIEH for people with responsibility for managing health and safety. They are so confident in their training team and methods that they offer a guaranteed pass on all IOSH and NEBOSH courses.
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.
MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.
Beauty Despite Cancer provides expertise in skincare for those living with and beyond cancer. Beauty Despite Cancer was founded in 2013 and was headquartered in Staffordshire, United Kingdom.
Nuclera is developing a bench-top gene and protein printer.
Helix Technologies is developing a range of compact, high-performance, dielectric-loaded ceramic antennas for use in a wide range of demanding telecommunications and navigation applications. The use of the ceramic core enables the fabrication of antennas that are physically smaller than conventional antennas, behave much more effectively and predictably in a wide range of challenging user scenarios and have many compelling technical advantages
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
Equity Crowdfunding in 2021
Operator of a craft brewing company intended to produce sustainable alcoholic beverages and decarbonize the wine industry. The company's platform offers high-quality, but accessible wines produced with the smallest possible climate impact and helps wine lovers everywhere discover the joy of drinking wine, which is packed in eco-friendly boxes, and cans, and sold in low-carbon packaging formats to continually reduce the carbon footprint of their products, thereby enabling consumers to enjoy their drinks in a healthy and environmentally sustainable way.
Developer of a lipid nanoparticle platform intended to provide better RNA vaccines. The company creates lipid products for use in building RNA vaccines for various diseases and offers systematic delivery of RNA molecules using targeted nanocarriers to the immune system with more transportable, with broader capabilities, and fewer side effects, enabling patients to have access to better vaccines and treatments.
Poundshop.com is an online retailer specializing in a wide range of household essentials. Founded in 2014 and based in Brierley Hill, United Kingdom, the company offers an extensive selection of products including clothing, watches, jewelry, drinks, groceries, snacks, body care, personal hygiene, and toiletries. Additionally, it provides items for DIY projects, gardening, kitchen needs, and products for babies, pets, and arts and crafts. With a commitment to delivering value, Poundshop.com operates as a single-price retailer, allowing customers to benefit from affordable prices compared to traditional retail outlets. The platform caters to customers across the United Kingdom and several European countries, ensuring convenience with home delivery services. The company has evolved since its inception, enhancing its website and expanding its product range to better serve its customers.
Unique IQ Ltd. specializes in developing software solutions for remote workforce management and electronic call monitoring. The company offers IQ:timecard, a web-based application that enables users to log care worker visits using landlines or mobile devices, manage time-critical visits, and send safety alerts for lone workers. Additionally, Unique IQ provides IQ:careplanner, a tool that facilitates the creation of schedules and care plans while optimizing the assignment of care workers based on various criteria, including distance to the visit and individual qualifications. Founded in 2003 and based in Redditch, United Kingdom, Unique IQ aims to enhance communication and operational efficiency for home care agencies, addressing the complexities of managing a mobile workforce.
Lineat is a manufacturer specializing in fiber tape products, particularly focusing on carbon fiber tapes produced through aligned formable fiber technology. This innovative approach allows for the creation of aligned discontinuous fiber tapes that demonstrate mechanical performance comparable to traditional continuous fiber composites. By simplifying the composite manufacturing process, Lineat enhances formability and streamlines both manual and automated operations. Additionally, the company has implemented a closed-loop water circulation system aimed at improving lifecycle assessment (LCA), reflecting its commitment to sustainability in production practices.
Inition is a company based in Didcot, England, focused on decarbonizing battery production and making the process accessible across various levels of the industry. It has developed proprietary technology that simplifies the manufacturing of electrodes, significantly reducing energy consumption during production. This innovative approach also minimizes the factory space required for production, thereby lowering operational costs. By enhancing the efficiency of battery manufacturing, Inition aims to support industries in accelerating their transition to renewable energy solutions.
Presymptom Health is a medtech company that specializes in developing clinical decision support algorithms and diagnostic tests aimed at early illness detection. The company focuses on pre-symptomatic diagnostics, allowing for the identification of conditions such as sepsis up to three days before symptoms manifest. By enabling earlier intervention, Presymptom Health's innovations aim to enhance critical care outcomes and improve patient management. Through its portfolio of blood tests and algorithms, the company seeks to transform the way healthcare providers approach patient care, ultimately contributing to better health outcomes and potentially saving lives.
Bitrobius Genetics is a developer of a DNA transfer technology designed to revolutionize gene and cancer therapy.
Crossfield Fusion develops a novel compact fusion reactor targeting carbon-free heat and power generation.
Stok.ly Ltd designs and develops a multi-channel retail software solution. The company’s software enables small to medium sized retailers to manage their business across multiple e-commerce platforms, incorporating stock control and ePos. Its software also allows to be integrated with retailers own websites, Facebook, eBay and other online retail channels. Stok.ly Ltd was founded in 2015 and is headquartered in Hereford, United Kingdom.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.
Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
azy Flora delivers hassle-free container gardens to busy people in the UK, on subscription. We take all the effort out of having a beautiful outdoor space, year round. Expertise on tap, no more weekend trips to the garden centre.
Midven is a venture capital firm located in Birmingham, United Kingdom, focusing on investing in early-stage and fast-growing small and medium-sized enterprises (SMEs). The firm provides financial support of up to £1 million, aiming to foster the growth of dynamic businesses. Midven is managed by an experienced team of investment professionals who take a hands-on approach to support the companies in their portfolio.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.
Connexica Limited designs and develops software that enables searches of structured and unstructured data, allowing the user to index, enquire, analyse and present large voloumes of corporate data in minutes. The company was formerly known as Ardentia Search Limited and changed its name to Connexica Limited in February, 2009. Connexica Limited was founded in 2006 and is based in Stafford, United Kingdom.
Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.
CFP Composites Ltd (formerly known as Carbon Fibre Preforms) is based in Dudley in the West Midlands, operating from a 28,000 square foot factory configured on a modular basis allowing for low-cost, rapid expansion. Offering a unique range of carbon fibre composite materials for extreme high temperature applications. CFP Composites’ technology enables composite materials to be produced significantly quicker, making the materials a commercially viable alternative to metal solutions.
Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
AMLo Biosciences Ltd is a company focused on developing diagnostic solutions for melanoma, specifically through its prognostic test, AMBLor. This test aims to accurately predict the risk of disease progression in patients diagnosed with early AJCC Stage I and Stage II melanoma. By identifying two specific proteins that are lost in high-risk melanomas, AMBLor helps to stratify patients for appropriate treatment and follow-up care. The company, incorporated in 2017 and based in Newcastle upon Tyne, United Kingdom, seeks to reduce the psychological burden on patients while also providing cost savings to health authorities by minimizing unnecessary patient surveillance.
D-RisQ Ltd. is a UK-based company that specializes in providing automated software verification tools aimed at enhancing system safety across various industries, including aerospace, automotive, and security. Founded in 2011 and located in Malvern, the company offers innovative solutions such as Kapture, which allows users to articulate software requirements clearly and verifiably, and Modelworks, which automates the verification of designs created in Simulink and Stateflow. By employing advanced formal methods of mathematical technology, D-RisQ's suite of tools streamlines the verification process from design to object code, significantly reducing the costs and time associated with traditional testing methods. This enables businesses to meet stringent regulatory standards without the extensive need for highly trained software engineers.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
Utility Stream Limited, established in 2018 and located in Warwick, United Kingdom, specializes in utility procurement and consultancy services, focusing on gas, electricity, and water. The company provides a range of energy services, including energy intelligence, voltage optimization, and metering and pipework solutions. It also offers comprehensive bureau services, which encompass customer portal access, account management, bill validation, and contract management, along with specialized multilingual support. Utility Stream aims to promote sustainability for businesses through its consultancy services, which include developing strategies to reduce energy usage and carbon footprints, ultimately helping companies save money while adopting more efficient energy practices.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Oneskee is an onine shopping company.
Beauty Despite Cancer provides expertise in skincare for those living with and beyond cancer. Beauty Despite Cancer was founded in 2013 and was headquartered in Staffordshire, United Kingdom.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
Attomarker is a spin-out company from the University of Exeter, a member of the UK’s Russell Group of research-intensive universities. The company’s founder, Professor Andrew Shaw, leads a team of scientists and engineers across the UK & Germany. Backed by six patents and referenced in 17 academic journals, Attomarker works. Realising the vision that has inspired many, but has, until now, proved so hard to turn into reality. Patented Attomarker technology collects the blood on a disposable credit-card sized chip which slots into a mobile pocket-sized devise, docked to an iPhone. The camera visualises the blood tests which are then interpreted by the iPhone. Test results can be shared, linked to electronic patient record systems and an AI Symptom checker for diagnosis. A tele-consultation will be available via the phone. Planned launch tests include Food Allergy (covering the eight food allergens that account for 95% of all), Pregnancy (replacing unreliable and undignified urine tests) and C-reactive protein, the 21st C thermometer, (identifying infection faster than changes in temperature). Research projects that will follow include fifth generation HIV testing, infectious diseases such as Zika and Ebola, Alzheimer’s, immunotherapy cohort surveillance, sepsis and a vitamin panel test. Attomarker intends to develop three sales channels - private doctors, pharmacies and direct to consumer.
Learning Labs operates an online educational platform designed to make language learning accessible to all students. The organization comprises a diverse team of former educators, linguists, and technology professionals who focus on enhancing engagement and learning outcomes in foreign language acquisition. By integrating lessons, games, and adaptive technology, the platform aims to foster effective learning experiences that help users improve their language skills and expand their vocabulary. The use of smartphones and tablets further facilitates this innovative approach to education, making language learning both engaging and effective.
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.
Norgrove Group operates as an e-commerce and building materials store, distributing a range of hardware, plumbing, and heating equipment and supplies. The company, originally known as Proplas Pvc Centre Limited, was incorporated in 2006 and rebranded to its current name in May 2017. It is located in Kidderminster, Worcestershire, and focuses on providing essential building materials to various customers in the construction and maintenance sectors.
CFP Composites Ltd (formerly known as Carbon Fibre Preforms) is based in Dudley in the West Midlands, operating from a 28,000 square foot factory configured on a modular basis allowing for low-cost, rapid expansion. Offering a unique range of carbon fibre composite materials for extreme high temperature applications. CFP Composites’ technology enables composite materials to be produced significantly quicker, making the materials a commercially viable alternative to metal solutions.
Ikarovec
Seed Round in 2020
Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Crossfield Fusion develops a novel compact fusion reactor targeting carbon-free heat and power generation.
Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.
Zipabout Limited is a UK-based company founded in 2011 that specializes in data aggregation and communication applications for the transport industry. The company has developed a big-data platform that integrates advanced technologies with extensive data sets to provide operational, environmental, and behavioral insights for passengers and transport operators. Zipabout focuses on delivering personalized passenger communications to facilitate seamless multi-modal journeys tailored to individual needs. Its innovative products, including the real-time Passenger Connect platform, provide essential knowledge and insights to policymakers, transport operators, and travelers, enhancing the overall travel experience.
The Supply Register Ltd. is a recruitment company specializing in the education sector. Founded in 2016 and based in Stoke-on-Trent, United Kingdom, the company has developed a cloud-based platform that provides a unified portal for schools, agencies, and teachers. This technology facilitates seamless connections and interactions among these stakeholders, enhancing the recruitment process within the educational landscape.
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
C-Major Medical is dedicated to addressing the persistent issue of needle stick injuries (NSIs) in medical environments. Despite significant efforts and legislation aimed at reducing these incidents, the frequency of NSIs has not declined sufficiently. To tackle this challenge, C-Major Medical develops innovative safety devices, including a syringe and blood collection system designed specifically to minimize the risk of NSIs and prevent contaminating aerosols. By promoting the safety of healthcare staff, the company's solutions aim to enhance practices in hospitals, clinics, and other medical settings, ultimately contributing to a safer working environment for medical practitioners.
CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.
Stok.ly Ltd designs and develops a multi-channel retail software solution. The company’s software enables small to medium sized retailers to manage their business across multiple e-commerce platforms, incorporating stock control and ePos. Its software also allows to be integrated with retailers own websites, Facebook, eBay and other online retail channels. Stok.ly Ltd was founded in 2015 and is headquartered in Hereford, United Kingdom.
Oneskee is an onine shopping company.
Quantum Group Solutions Limited, based in Knowle, Solihull, United Kingdom, specializes in recruitment services, including outplacement and employment vacancy listing. The company assists organizations by referring applicants for various positions, ensuring that the individuals referred are not employees of the employment agencies. Founded in 2000 and originally named Quantum Search & Selection Limited, the company rebranded in January 2010 to reflect its broader service offerings.
Arctoris Limited, founded in 2016 and headquartered in Oxford, United Kingdom, operates the world’s first fully automated drug discovery platform. The company provides an online platform that facilitates data generation, secure storage, analysis, and visualization for researchers and biotech entrepreneurs engaged in cellular and molecular biology experiments. Utilizing advanced robotics and artificial intelligence, Arctoris enables rapid and cost-effective access to a variety of biochemical, cell-based, and molecular biology assays. This automation allows clients, including biotech and pharmaceutical companies as well as academic institutions, to make informed decisions based on high-quality, structured data. By streamlining the drug discovery process, Arctoris aims to accelerate the advancement of new drug programs towards clinical application.
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process.
HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Congenica Ltd. is a UK-based company that specializes in clinical data solutions for genetic diagnosis. Founded in 2012, it leverages pioneering research from the Wellcome Trust Sanger Institute and NHS clinicians to develop its flagship product, the Sapientia platform. This clinical genomic analytics tool integrates human DNA sequences with deep clinical phenotyping, allowing clinicians and researchers to interpret genetic diseases effectively. Sapientia supports clinical diagnosis, prognosis, and research, and plays a crucial role in personalized medicine applications, including the creation of disease registries and the identification of patient populations for clinical studies. By providing diagnostic decision support and associated services, Congenica aims to enhance patient care through precise diagnoses and the curation of evolving knowledge bases, ultimately contributing to advancements in clinical trials and drug development.
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.
MyoDOPA
Funding Round in 2019
MyoDOPA is develops a novel therapeutic profile providing efficient treatment.
Oxford Brain Diagnostics Ltd develops a Cortical Disarray Measurement (CDM) platform that uses magnetic resonance imaging (MRI) scans for clinical research and diagnosis to track the progress of dementia. The tool provides an index of the health of the cellular circuits in a patient's brain. The micro-structural assessment provides an analysis regarding the probability of developing dementia after studying the memory complaints. The company was incorporated in 2018 and is based in Oxford, United Kingdom.
MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the progression of challenging diseases, particularly rare indications, while also engaging in partnerships for broader applications. Their work enables healthcare professionals to potentially halt the decline associated with dystrophy and neurodegeneration.
PragmatIC Semiconductor specializes in the design and manufacture of flexible integrated circuits, known as FlexICs, which are thinner than a human hair and can be embedded in various objects. This technology allows for the creation of innovative solutions that traditional electronics cannot easily achieve. The company's offerings include a range of products such as application-specific FlexICs through its FlexIC Foundry service, as well as standard products like the ConnectIC family, which supports applications like RFID and NFC. PragmatIC's manufacturing process utilizes the FlexLogIC production system, enabling efficient and cost-effective high-volume production. The company serves a diverse clientele across sectors such as consumer goods, packaging, healthcare, and security. Founded in 2006 and based in Cambridge, UK, with an additional facility in Sedgefield, PragmatIC is recognized as a leader in ultra-low-cost flexible electronics.
Smart Green Shipping specializes in creating innovative, digitally enabled wind-powered solutions for the maritime industry. The company has developed data-driven wing sails that optimize merchant shipping routes through advanced software. By utilizing meteorological and satellite data, Smart Green Shipping's system projects annual fuel savings for shipping companies, whether they retrofit existing vessels or incorporate the technology into new builds. This approach not only promotes the adoption of wind assist technologies but also aims to enhance operational efficiency and reduce fuel consumption in shipping operations.
Pireta Ltd is a company focused on developing and commercializing technology for smart textiles. Established in 2017 and based in Teddington, United Kingdom, Pireta has created a unique additive process that integrates conductivity and sensors into fabrics without altering their feel or performance. This innovative approach enables the production of textiles that can serve various functions, including communication, physiological monitoring, and tracking. Pireta's technology is applicable across multiple industries, such as military, emergency services, defense, fashion, athletics, healthcare, biosciences, and RFID tagging, facilitating the creation of wearable smart garments and electronic textiles.
Nuclera is developing a bench-top gene and protein printer.
CFP Composites Ltd (formerly known as Carbon Fibre Preforms) is based in Dudley in the West Midlands, operating from a 28,000 square foot factory configured on a modular basis allowing for low-cost, rapid expansion. Offering a unique range of carbon fibre composite materials for extreme high temperature applications. CFP Composites’ technology enables composite materials to be produced significantly quicker, making the materials a commercially viable alternative to metal solutions.
Oxford VR Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing automated cognitive treatments for various clinical conditions, including fear of heights, psychosis, and social anxiety. Originating from research at Oxford University by Professor Daniel Freeman, the company harnesses immersive virtual reality technology to deliver therapy through a virtual coach. This innovative approach aims to significantly increase access to mental health treatments, making them faster, more effective, and lower in cost compared to traditional methods. Oxford VR focuses on creating clinically validated and user-centered therapies that not only benefit patients but also positively impact the healthcare system and the broader economy.
CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.
Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.
Connexica Limited designs and develops software that enables searches of structured and unstructured data, allowing the user to index, enquire, analyse and present large voloumes of corporate data in minutes. The company was formerly known as Ardentia Search Limited and changed its name to Connexica Limited in February, 2009. Connexica Limited was founded in 2006 and is based in Stafford, United Kingdom.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
Oxford Space Systems Limited is a space technology company based in Harwell, United Kingdom, founded in 2013. The firm specializes in developing, manufacturing, and marketing deployable hardware structures for space applications, including deployable antennas, composite linear boom systems, and hinge systems. By employing innovative design techniques, such as origami, and utilizing novel proprietary materials, Oxford Space Systems creates products that are lighter, less complex, and more cost-effective than traditional alternatives. The company has achieved significant milestones, including a record for the fastest development of a new product, the AstroTube Boom, which was successfully deployed in orbit within 30 months. With a team of 18 professionals possessing over 100 years of combined experience in the space sector, Oxford Space Systems has engaged in various collaborations, including government-supported projects with leading European satellite manufacturers and commercial contracts in Asia and the U.S. In 2018, the company relocated to a custom facility within the Harwell Space Cluster, enhancing its capabilities to meet security standards for defense and security contracts.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.